Evaluation of the PhageTech Virus BioResistor

Status unconfirmed

Conditions studied: Bladder Cancer

In brief

To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.

Key facts

Study ID

NCT04756284

Run by

PhageTech, Inc.

People needed

50

Starts

2021-02-08

Expected to finish

2021-11-11

Last updated by the study team

2021-02-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and female patients ≥ 18 years
• Previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy
• Patients with suspected bladder tumor undergoing surveillance cystoscopy
• Patients must provide written Informed Consent.

You may not qualify if…

• Patients unable or unwilling to sign the informed consent
• Age < 18 years
• Known HIV/HCV/HBV (information from clinical history).

Where it is running

• Providence Saint John's Health Center and the Saint John's Cancer Institute — Santa Monica, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.